All In Biotech

Drug Trial Radar · NCT07419334

Study of ALK-001 on the Progression of Stargardt Disease

A Phase 3 Multicenter, Double-Masked, Randomized, Placebo-Controlled Study to Investigate the Safety, Tolerability, and Efficacy of Gildeuretinol Acetate (ALK 001) on the Progression of Stargardt Disease (STGD)

Last checked: Nov 19, 2026Latest source record: Sep 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 230 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

230

Planned (sponsor's estimate)

Start

Jun 3, 2026

Primary completion

Oct 2029

Study completion Dec 2030

Sponsor

Lead sponsor
Alkeus Pharmaceuticals, Inc.Industry
Sponsor type
Industry
First posted
Feb 19, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 8 years, up to 45 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study evaluates the efficacy and safety of investigational study drug ALK-001 in participants 8 to 45 years of age, inclusive, with symptoms and signs of autosomal recessive Stargardt disease (STGD)

Conditions

  • Stargardt Disease

Interventions

  • ALK-001Drug

    Daily oral administration for 24 months

  • PlaceboDrug

    Daily oral administration for 24 months

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Annualized growth rate of retinal atrophic lesions measured by Fundus AutofluorescenceTime frame: Month 6 to Month 24

Locations

14 sites in 1 country. Site status is shown where the registry gives one.

  • Associated Retina Consultants

    Phoenix, Arizona · Recruiting

  • University of Colorado SOM, Sue-Anschutz-Rodgers Eye Center

    Aurora, Colorado · Recruiting

  • Vitreo Retinal Associates

    Gainesville, Florida · Recruiting

  • Tufts Medical Center - New England Eye Center

    Boston, Massachusetts · Not yet recruiting

  • Foundation for Vision Research

    Grand Rapids, Michigan · Recruiting

  • Ohio State Havener Eye Institute

    Columbus, Ohio · Recruiting

  • Erie Retina Research

    Erie, Pennsylvania · Recruiting

  • Mid Atlantic Retina

    Philadelphia, Pennsylvania · Not yet recruiting

  • UPMC Vision Institute

    Pittsburgh, Pennsylvania · Recruiting

  • Retina Foundation of the Southwest

    Dallas, Texas · Recruiting

  • Star Retina

    Fort Worth, Texas · Recruiting

  • Medical Center Ophthalmology Associates

    San Antonio, Texas · Recruiting

  • The Retina Group of Washington

    Fairfax, Virginia · Recruiting

  • Wagner Kapoor Research Institute

    Norfolk, Virginia · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.